Breast Cancer: Translational Therapeutic Strategies

— —

Gary H. Lyman (Duke University) Harold J. Burstein (Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts, USA)

Breast Cancer

Translational Therapeutic Strategies

Gary H. Lyman (Duke University), Harold J. Burstein (Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts, USA), Kathy D. Miller (Indiana University, Indianoplis, USA) , Harold J. Burstein (Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts, USA)

$231

Hardback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

CRC Press Inc
29 January 2007

Diseases & disorders; Oncology

Series: Translational Medicine

Considering the impact of translational breakthroughs on the early detection, diagnosis, prevention, and treatment of breast cancer, this all-encompassing guide collects cutting-edge research on the most promising strategies and agents likely to impact the management and long-term outcomes of women with breast cancer. This book will provide current information on rapidly evolving translational therapies, as well as improved strategies for the selection of patients for these treatments.

Contributions by: Kathy D. Miller (Indiana University Indianoplis USA), Lodovico Balducci (H. Lee Moffitt Cancer Center, Tampa, Florida, USA)
Edited by: Gary H. Lyman (Duke University), Harold J. Burstein (Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts, USA), Harold J. Burstein (Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts, USA)
Imprint: CRC Press Inc
Country of Publication: United States
Volume: 2
Dimensions: Height: 229mm, Width: 152mm, Spine: 22mm
Weight: 589g
ISBN: 9780849374166
ISBN 10: 0849374162
Series: Translational Medicine
Pages: 344
Publication Date: 29 January 2007
Audience: Professional and scholarly , Undergraduate
Format: Hardback
Publisher's Status: Active

METHODS AND FRAMEWORK. Clinical Trials of Novel and Targeted Therapies: Endpoints, Trial Design, and Analysis. Prognostic models: A Methodological Framework and Review of Models for Breast Cancer. Challenges of Microarray Data and the Evaluation of Gene Expression Profile Signatures. Preoperative Therapy as a Model for Translational Research in Breast Cancer. Pharmacology And Pharmacogenetics of Chemotherapeutic Agents. Aging, Cancer, and Translational Research. MOLECULAR AND CELLULAR MARKERS OF PROGNOSIS. The Prognostic Implications of Circulating Tumor Cells in Patients with Breast Cancer. The Prognostic Impact of Bone Marrow Micrometastases in Women with Breast Cancer. The Prognostic Importance of Isolated Tumor Cell Clusters and Micrometastases in Sentinel Lymph Nodes. Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer. Development and Validation of Gene Expression Profile Signatures in Early-Stage Breast Cancer. Gene Expression Profile Assays as Predictors of Distant Recurrence-Free Survival in Early Stage Breast Cancer. Economic Analysis of Gene Expression Profile Data to Guide Adjuvant Treatment in Women with Early-Stage Breast Cancer. NOVEL THERAPIES AND TREATMENT. Aromatase Inhibitors for Breast Cancer Treatment and Prevention. Fulvestrant: A Novel Hormonal Agent. HER2-Positive Breast Cancer: Current Treatment Strategies. Is there a Role for ErbB Dual Kinase Inhibition?. Anti-Epidermal Growth Factor Receptor Strategies for Advanced Breast Cancer. Farnesyl Transferase Inhibitors. nab-Paclitaxel: Reducing Toxicity Using Albumin-Bound Particles as the Carrier for Paclitaxel. The Epothilones. Antiangiogenic Agents in Breast Cancer. Epigenetic Regulation as a New Target for Breast Cancer Therapy. Tumor Vaccines for Breast Cancer

Lyman, Gary H.; Burstein, Harold J.